Back to results
US 8,911,933 B2Granted
DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
AssigneeThe University of North Carolina at Chapel Hill
InventorsYi Zhang, Qin Feng
Life of this patent
Estimating the term…
Abstract
The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject.
Claims14
A method of identifying a compound that modulates DOT1L histone H3 lysine 79 (H3-K79) methyltransferase activity, comprising:
- contacting a DOT1L polypeptide with a nucleosome substrate comprising histone H3 in the presence of a test compound;
- wherein the DOT1L polypeptide comprises an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence of SEQ ID NO:2;
- (b) an amino acid sequence having at least 95% amino acid sequence similarity with the amino acid sequence of SEQ ID NO:2, wherein said DOT1L polypeptide has H3-K79 methyltransferase activity;
- and
- (c) a functional fragment of at least 400 amino acids of the amino acid sequence of (a) or (b) above, wherein said functional fragment comprises a DOT1L histone methyltransferase catalytic domain and has H3-K79 methyltransferase activity;
- detecting the level of H3-K79 methylation of the nucleosome substrate under conditions sufficient to provide H3-K79 methylation,
- wherein an elevation or reduction in H3-K79 methylation in the presence of the test compound as compared with the level of histone H3-K79 methylation in the absence of the test compound indicates that the test compound modulates DOT1L H3-K79 methyltransferase activity.
5 more elements
Dependencies are inferred from the claim text.